Skip to main
BDSX

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix is positioned for continued success due to their strong financial performance, expanding market share, and innovative product pipeline. However, they face competition in the diagnostic testing industry and must continue to invest in research and development to stay ahead. Overall, the company shows promise in both financial growth and scientific advancements, making it a positive investment opportunity for the future.

Bears say

Biodesix is heavily reliant on its Nodify portfolio of blood-based lung screening tests for its current and future success, which holds a significant market opportunity of 10 million annual testing opportunities and $27 billion annual market. However, there are several risks to achieving the projected price target, including competition from upcoming competitors, potential low revenue growth, and inability to achieve sustainable profitability. Additionally, the company's reliance on timely and favorable reimbursement decisions may also impact its future revenue growth.

Biodesix (BDSX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.